Drug development continues to advance understanding about causes of disease, as well as to innovate therapeutic modalities. Yet, the process remains time intensive, costly, and high risk. The average drug takes over 10 years and $1 billion–$2 billion to be approved for clinical use— yet 90% of new drugs reaching Phase I clinical trials ultimately fail to reach approval.
This high risk of failure, along with the substantial investment of time, labor, and financial resources put into every new drug candidate, poses a persistent challenge for drug developers. To ensure the efficient use of development resources and the creation of safe, effective, and reliable products for patients, drugmakers must take steps to de-risk development at every step. In this e-book, learn about three tools that drug developers can use to successfully navigate the journey from candidate compound to clinical success.
Download the e-book to discover three tools that facilitate a successful journey from candidate compound to clinical triumph:
- Solid form screening: useful at development stages from lead form identification to intellectual property protection
- Physiologically based pharmacokinetic (PBPK) modeling: provides a deeper view into how a drug behaves in the body while accounting for patient variability
- Route scouting: how including real word supply chain information in a retrosynthetic analysis can deliver synthetic routes with reduced cost and risk